LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
REBN
Reborn Coffee, Inc.
There isn't enough reported data to score REBN yet.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
REBN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
REBN's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
REBN PE Valuation
REBN has no meaningful PE right now: it lost money over the past year.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
REBN Forward outlook
There aren't enough analyst estimates for REBN to show an outlook.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
REBN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.65 | +$1.55 |
| Q1 2026 | -$1.48 | +$0.05 |
| Q4 2025 | -$1.73 | -$0.07 |
| Q3 2025 | -$2.58 | -$0.23 |
| Q2 2025 | -$2.20 | +$0.33 |
| Q1 2025 | -$1.53 | +$1.32 |
| Q4 2024 | -$1.66 | +$1.23 |
| Q3 2024 | -$2.35 | +$0.35 |
REBN has the edge over LCID on earnings, with more consistent year-over-year improvement.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over REBN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
REBN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $6.3M | +245% |
| Q1 2026 | $5.2M | +208% |
| Q4 2025 | $3.2M | +80% |
| Q3 2025 | $1.4M | +7.8% |
| Q2 2025 | $1.8M | +34% |
| Q1 2025 | $1.7M | +12% |
| Q4 2024 | $1.8M | +31% |
| Q3 2024 | $1.3M | -17% |
REBN's revenue has grown year over year for seven quarters in a row: $6M last quarter, up 245% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -25% | +215 points |
| Q1 2026 | -17% | +84 points |
| Q4 2025 | 105% | +200 points |
| Q3 2025 | -225% | -167 points |
| Q2 2025 | -240% | -143 points |
| Q1 2025 | -100% | -43 points |
| Q4 2024 | -95% | +27 points |
| Q3 2024 | -58% | -9.2 points |
REBN has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
REBN has the stronger cash trend. Its trailing FCF is down 42% versus its history, compared with LCID at down 75%.
REBN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$1.7M | -$1.1M |
| Q3 2025 | -$1.6M | -$1.2M |
| Q4 2024 | -$600.9K | +$1.3M |
| Q3 2024 | -$424K | -114% |
| Q2 2024 | -$615.9K | +$4M |
| Q1 2024 | -$2.9M | -$786.7K |
| Q4 2023 | -$1.9M | -$206.3K |
| Q3 2023 | $3M | +$3.9M |
REBN has burned cash in almost every quarter: −$5M over the past year, against −$5M the year before.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has the edge over REBN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
REBN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +78% | +3.6M shares |
| 3 years | +440% | +6.7M shares |
REBN has 8M diluted shares, up 78% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
REBN Net Leverage
REBN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
REBN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.7 | Neutral |
| Stochastic | 38.7 | Neutral |
REBN's weekly RSI is 43 (neutral) and its Stochastic is 39 (neutral).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
REBN PE vs Consumer Cyclical Sector
REBN has no meaningful PE right now: it lost money over the past year.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
REBN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.54 | 32% below |
| 20 week MA | $1.37 | 23% below |
| 50 week MA | $1.69 | 38% below |
| 100 week MA | $2.21 | 52% below |
| 200 week MA | $3.34 | 69% below |
REBN is in a downtrend: it's below all five of its weekly moving averages, and 69% below its 200-week average.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
REBN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $38.4 | $6.24 | -84% |
| 2023 | $6.24 | $4.56 | -27% |
| 2024 | $4.56 | $1.80 | -61% |
| 2025 | $1.80 | $1.47 | -18% |
| 2026 YTD | $1.47 | $1.05 | -29% |
REBN has the edge over LCID on returns for 2026, with the stronger performance.